TipRanks
Context Therapeutics (CNTX)
NASDAQ:CNTX
US Market
CNTX
Context Therapeutics
RESEARCH TOOLSreports
Want to see CNTX full AI Analyst Report?

Context Therapeutics (CNTX) Stock News & Sentiment

325 Followers
Analyst Reiterates Buy on Context Therapeutics, Maintains $4 Price Target Amid Promising CTIM‑76 Data and Compelling Valuation
Premium
Ratings
Analyst Reiterates Buy on Context Therapeutics, Maintains $4 Price Target Amid Promising CTIM‑76 Data and Compelling Valuation
2M ago
CNTX
Analyst Reaffirms Buy on Context Therapeutics, Citing Undervalued Pipeline and CTIM-76 as Key Long-Term Driver
Premium
Ratings
Analyst Reaffirms Buy on Context Therapeutics, Citing Undervalued Pipeline and CTIM-76 as Key Long-Term Driver
2M ago
CNTX
Analyst Reiterates Buy on CTI with Unchanged $5 Price Target, Citing CTIM-76 Differentiation and Strategic Focus on CT-202
Premium
Ratings
Analyst Reiterates Buy on CTI with Unchanged $5 Price Target, Citing CTIM-76 Differentiation and Strategic Focus on CT-202
2M ago
CNTX
Context Therapeutics Highlights Progress in T Cell Engager Pipeline
Premium
Company Announcements
Context Therapeutics Highlights Progress in T Cell Engager Pipeline
2M ago
8K
CNTX
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice
Premium
Company Announcements
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice
2M ago
8K
CNTX
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst
Premium
Company Announcements
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst
3M ago
CNTX
Context Therapeutics Shareholders Approve Stock Increase and Directors
Premium
Company Announcements
Context Therapeutics Shareholders Approve Stock Increase and Directors
3M ago
8K
CNTX
More CNTX News >

CNTX News on the Web

Analyst Reiterates Buy on Context Therapeutics, Maintains $4 Price Target Amid Promising CTIM‑76 Data and Compelling Valuation
TipRanks News
Bullish
Context Therapeutics Shareholders Approve Stock Increase and Directors
TipRanks News
Neutral
Context Therapeutics Inc to Discuss CTIM-76 Phase 1 Interim Results Transcript
GuruFocus News
Neutral
Context Therapeutics selloff brings buying opportunity, says JonesResearch
TipRanks News
Neutral
Boris Peaker Reiterates Buy on Context Therapeutics, Maintains $7 Price Target on Promising CTIM-76 Data and Attractive Risk/Reward
TipRanks News
Bullish
Charles Zhu Reiterates Buy on Context Therapeutics, Citing Encouraging CTIM-76 Efficacy, Favorable Safety, and De‑Risked Development Outlook
TipRanks News
Neutral
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
TipRanks News
Neutral
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
TipRanks News
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0.25 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CNTX’s Media Buzz Sentiment?
Currently, no data Available
What is CNTX’s weekly average amount of articles?
In an average week, 0.25 articles about CNTX are published.
    What is CNTX’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    REGNRegeneron
    QTTBQ32 Bio
    NVSNovartis
    RHHVFRoche Holding AG
    KRROKorro Bio
    Showing the stocks with the most bullish news sentiment over the past week